Learn about Ductal Carcinoma In Situ (DCIS) of the breast, also known as intraductal carcinoma or non-invasive breast cancer. This page provides information on DCIS diagnosis, clinical documentation, and medical coding for healthcare professionals. Find details on ICD-10 codes, staging, treatment options, and best practices for accurate reporting and patient care related to DCIS and non-invasive breast cancer.
Also known as
In situ neoplasms of breast
Non-invasive breast cancers confined to milk ducts or lobules.
Malignant neoplasm of breast
Invasive breast cancers that have spread beyond the ducts or lobules.
Personal history of malignant neoplasm of breast
Indicates a past diagnosis of breast cancer, now treated or resolved.
Encounter for screening mammogram for malignant neoplasm of breast
Represents a visit specifically for breast cancer screening.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the DCIS purely ductal?
When to use each related code
| Description |
|---|
| Non-invasive breast cancer inside milk ducts. |
| Invasive breast cancer spread beyond milk ducts. |
| Breast cancer originating in lobules. |
Missing or incorrect laterality (right, left, bilateral) for DCIS impacts staging and treatment data accuracy. CDI crucial.
Accurate coding of grade (e.g., high/low) or type (e.g., comedo, cribriform) is essential for proper treatment and prognosis.
Confusing DCIS (non-invasive) with invasive ductal carcinoma leads to significant coding errors affecting quality metrics and reimbursement.
Q: What are the most effective surgical management strategies for low-grade DCIS (Ductal Carcinoma In Situ) with microcalcifications detected on mammography?
A: Surgical management of low-grade DCIS with microcalcifications needs to balance minimizing recurrence risk with avoiding overtreatment. While mastectomy offers the lowest local recurrence rates, breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) is often preferred for suitable candidates. Factors influencing surgical strategy choice include the extent of DCIS, presence of comedo necrosis, patient preference, and multifocality/multicentricity. Oncotype DX DCIS Score can help assess individualized recurrence risk after BCS and guide decisions regarding WBI. Explore how incorporating molecular profiling can refine surgical planning for low-grade DCIS. Additionally, carefully evaluating margin status during BCS is critical; consider implementing intraoperative margin assessment techniques to reduce re-excision rates. For extensive or multifocal/multicentric low-grade DCIS, mastectomy may be the more appropriate approach.
Q: How do I differentiate between DCIS (Ductal Carcinoma In Situ), invasive ductal carcinoma, and atypical ductal hyperplasia (ADH) based on pathology findings, and what are the implications for treatment planning?
A: Differentiating DCIS, invasive ductal carcinoma, and ADH relies on careful histopathological evaluation. ADH exhibits some architectural and cytological atypia but lacks the complete filling of ducts characteristic of DCIS. DCIS is confined within the breast ducts without basement membrane invasion, whereas invasive ductal carcinoma demonstrates stromal invasion. Distinguishing between these entities is crucial for treatment planning. ADH may be managed with close observation or excision, while DCIS requires surgical excision, often with radiation therapy. Invasive ductal carcinoma necessitates a more comprehensive approach, including surgery, potentially radiation, and systemic therapy (chemotherapy, hormone therapy, or targeted therapy) depending on the stage and characteristics of the tumor. Immunohistochemical markers, such as E-cadherin and myoepithelial markers (p63, calponin), can aid in distinguishing in situ from invasive disease. Learn more about the role of immunohistochemistry in breast pathology for accurate diagnosis and treatment stratification. Consider implementing a multidisciplinary approach involving pathologists, radiologists, and oncologists to ensure optimal management based on the precise diagnosis.
Patient presents with concerns regarding breast health. Initial complaint may include abnormal mammogram findings, palpable breast lump, or nipple discharge. On physical exam, findings may include breast asymmetry, skin changes such as thickening or dimpling, or nipple retraction. Mammography revealed suspicious microcalcifications prompting further evaluation. Biopsy results confirm a diagnosis of ductal carcinoma in situ (DCIS), also known as intraductal carcinoma or non-invasive breast cancer. This pre-cancerous condition is confined to the milk ducts of the breast and has not invaded surrounding tissues. Diagnostic workup includes breast imaging, such as diagnostic mammogram, ultrasound, and potentially MRI. The grade of DCIS, based on cellular features, will be determined. Treatment options for ductal carcinoma in situ include surgical excision (lumpectomy or mastectomy), radiation therapy, and potentially hormonal therapy such as tamoxifen or an aromatase inhibitor to reduce recurrence risk. The patient's specific treatment plan will be discussed and tailored based on the size, grade, and location of the DCIS, as well as patient preference and overall health status. Patient education regarding DCIS prognosis, follow-up care, and breast cancer risk factors will be provided. Appropriate ICD-10 coding (D05.0) and CPT coding for procedures performed will be documented. Follow-up appointments will be scheduled for ongoing surveillance and management.